Effect of cationic drugs on the transporting activity of human and rat OCT/Oct 1-3 in vitro and implications for drug-drug interactions

Xenobiotica

Volumn 38, Issue 9, 2008, Pages 1203-1218

  Umehara, K I ^a   Iwatsubo, T ^a   Noguchi, K ^a   Usui, T ^a   Kamimura, H ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Cationic compounds; Drug drug interaction; hOCT rOct; Inhibition

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; AMIODARONE; ATENOLOL; CEFALEXIN; CIMETIDINE; DILTIAZEM; FLECAINIDE; LEVOFLOXACIN; LIDOCAINE; METFORMIN; METOPROLOL; N [2 [3 (6,7 DIMETHOXY 1,2,3,4 TETRAHYDROISOQUINOLINE 2 CARBONYL)PIPERIDINO]ETHYL] 4 FLUOROBENZAMIDE MONOPHOSPHATE; OCTAMER TRANSCRIPTION FACTOR 1; OCTAMER TRANSCRIPTION FACTOR 2; OCTAMER TRANSCRIPTION FACTOR 4; OXPRENOLOL; PINDOLOL; PROCAINAMIDE; PROPRANOLOL; QUINIDINE; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; YM 758;

ANIMAL CELL; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG INTERACTION; DRUG MECHANISM; DRUG UPTAKE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; KIDNEY; LIVER CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SPECIES DIFFERENCE;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTI-BACTERIAL AGENTS; BENZAMIDES; CATIONS; CELL LINE; CIMETIDINE; DRUG INTERACTIONS; HISTAMINE H2 ANTAGONISTS; HUMANS; ISOQUINOLINES; LIDOCAINE; METFORMIN; ORGANIC CATION TRANSPORT PROTEINS; PROCAINAMIDE; QUINIDINE; RATS;

RATTUS;

EID: 50249105275     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250802334409     Document Type: Article

References (37)

1. Bauer LA, Black DJ, Lill JS, Garrison J, Raisys VA, Hooton TM. 2005. Levofloxacin and ciprofloxacin decrease procainamide and N-acetylprocainamide renal clearances. Antimicrobial Agents and Chemotherapy 49:1649-1651.
2. Bucchi A, Barbuti A, Baruscotti M, DiFrancesco D. 2007. Heart rate reduction via selective 'funny' channel blockers. Current Opinion in Pharmacology 7:208-213.
3. Ding R, Tayrouz Y, Riedel KD, Burhenne J, Weiss J, Mikus G, Haefeli WE. 2004. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clinical Pharmacology and Therapeutics 76:73-84.
4. Dudley AJ, Bleasby K, Brown CD. 2000. The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers. British Journal of Pharmacology 131:71-79.
5. Ekaratanawong S, Anzai N, Jutabha P, Miyazaki H, Noshiro R, Takeda M, Kanai Y, Sophasan S, Endou H. 2004. Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules. Journal of Pharmacological Sciences 94:297-304.
6. El-Sheikh AA, Van den Heuvel JJ, Koenderink JB, Russel FG. 2007. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. Journal of Pharmacology and Experimental Therapeutics 320:229-235.
7. Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, Baumann C, Lang F, Busch AE, Koepsell H. 1997. Cloning and characterization of two human polyspecific organic cation transporters. DNA and Cell Biology 16:871-881.
8. Grundemann D, Gorboulev V, Gambaryan S, Veyhl M, Koepsell H. 1994. Drug excretion mediated by a new prototype of polyspecific transporter. Nature 372:549-552.
9. Hardman JG, Molinoff PB, Ruddon RW, Gilman AG. 1996. Goodman & Gilman's: The pharmacological basis of therapeutics, 9th ed. New York, NY: McGraw-Hill.
10. Indolfi C, Guth BD, Miura T, Miyazaki S, Schulz R, Ross Jr J. 1989. Mechanisms of improved ischemic regional dysfunction by bradycardia. Studies on UL-FS 49 in swine. Circulation 80:983-993.
11. Jayasagar G, Krishna Kumar M, Chandrasekhar K, Madhusudan Rao C, Madhusudan Rao Y. 2002. Effect of cephalexin on the pharmacokinetics of metformin in healthy human volunteers. Drug Metabolism and Drug Interactions 19:41-48.
12. Katoh M, Suzuyama N, Takeuchi T, Yoshitomi S, Asahi S, Yokoi T. 2006. Kinetic analyses for species differences in P-glycoprotein-mediated drug transport. Journal of Pharmaceutical Sciences 95:2673-2683.
13. Kekuda R, Prasad PD, Wu X, Wang H, Fei YJ, Leibach FH, Ganapathy V. 1998. Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. Journal of Biological Chemistry 273:15971-15979.
14. Lai MY, Jiang FM, Chung CH, Chen HC, Chao PD. 1988. Dose dependent effect of cimetidine on procainamide disposition in man. International Journal of Clinical Pharmacology, Therapy, and Toxicology 26:118-121.
15. +/peptide symporter PEPT2: Analysis of affinity constants and comparison with PEPT1. European Journal of Pharmaceutics and Biopharmaceutics 59:17-24.
16. Masuda S. 2003. Functional characteristics and pharmacokinetic significance of kidney-specific organic anion transporters, OAT-K1 and OAT-K2, in the urinary excretion of anionic drugs. Drug Metabolism and Pharmacokinetics 18:91-103.
17. Motohashi H, Uwai Y, Hiramoto K, Okuda M, Inui K. 2004. Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). European Journal of Pharmacology 503:25-30.
18. Okuda M, Saito H, Urakami Y, Takano M, Inui K. 1996. cDNA cloning and functional expression of a novel rat kidney organic cation transporter, OCT2. Biochemical and Biophysical Research Communications 224:500-507.
19. Okuda M, Urakami Y, Saito H, Inui K. 1999. Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes. Biochimica et Biophysica Acta 1417:224-231.
20. Ragueneau I, Laveille C, Jochemsen R, Resplandy G, Funck-Brentano C, Jaillon P. 1998. Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clinical Pharmacology and Therapeutics 64:192-203.
21. Roth W, Bauer E, Heinzel G, Cornelissen PJ, Van Tol RG, Jonkman JH, Zuiderwijk PB. 1993. Zatebradine: Pharmacokinetics of a novel heart-rate-lowering agent after intravenous infusion and oral administration to healthy subjects. Journal of Pharmaceutical Sciences 82:99-106.
22. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, et al. 2007. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. Journal of Clinical Investigation 117:1422-1431.
23. Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. 1987. Reduction of metformin renal tubular secretion by cimetidine in man. British Journal of Clinical Pharmacology 23:545-551.
24. Takane H, Shikata E, Otsubo K, Higuchi S, Ieiri I. 2008. Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics 9:415-422.
25. 2-blockers on the organic cation transporters-mediated transport between human (OCT) and rat (oct): Insight into the application to the development of drug candidates. Xenobiotica 37:618-634.
26. Umehara KI, Iwatsubo T, Noguchi K, Kamimura H. 2007b. Functional involvement of organic cation transporter1 (OCT1/Oct1) in the hepatic uptake of organic cations in humans and rats. Xenobiotica 37:818-831.
27. Umehara KI, Iwatsubo T, Noguchi K, Kamimura H. 2008a. Functional involvement of the organic cation transporter 2 (rOct2) in the renal uptake of organic cations in rats. Journal of International Medical Research 36:123-136.
28. f channel inhibitor, in albino and non-albino rats. Xenobiotica 38:527-539.
29. Van Crugten J, Bochner F, Keal J, Somogyi A. 1986. Selectivity of the cimetidine-induced alterations in the renal handling of organic substrates in humans. Studies with anionic, cationic and zwitterionic drugs. Journal of Pharmacology and Experimental Therapeutics 236:481-487.
30. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y. 2002. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. Journal of Pharmacology and Experimental Therapeutics 302:510-515.
31. Wang DS, Kusuhara H, Kato Y, Jonker JW, Schinkel AH, Sugiyama Y. 2003. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Molecular Pharmacology 63:844-848.
32. Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway SJ, Leibach FH, Ganapathy V. 2000. Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. AJP: Renal Physiology 279:F449-F458.
33. Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J, Conway SJ, Ganapathy V. 1999. Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. Journal of Pharmacology and Experimental Therapeutics 290:1482-1492.
34. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A. 1999. Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. Journal of Pharmacology and Experimental Therapeutics 289:768-773.
35. Yokoo S, Yonezawa A, Masuda S, Fukatsu A, Katsura T, Inui K. 2007. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochemical Pharmacology 74:477-487.
36. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM. 1997. Cloning and functional expression of a human liver organic cation transporter. Molecular Pharmacology 51:913-921.
37. Zhou SF, Xue CC, Yu XQ, Li C, Wang G. 2007. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Therapeutic Drug Monitoring 29:687-710.